In advanced lung cancer, PD-1 blockade therapy and anti-CTLA-4 antibody drug therapy have resulted in long-term survival in 20%–30% of patients, and it is believed that the main mechanism by which T-cell immunity is weakened is T-cell exhaustion (6, 22). Here, PDCD1 is linked to lung carcinoma.